GlassScriptPhysician profile
Alexander C Keszeli
NPI 1588652184
$2,821.36
in general payments reported to CMS, 2019-2025
32 companies · $545 in 2025
The $545 reported for 2025 was more than what a typical Otolaryngic Allergy provider received nationally (typical 2025 total: $449).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $342 · 2021: $309 · 2022: $357 · 2023: $442 · 2024: $416 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,269 · Education: $98.99 · Consulting Fee: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.61 |
| Education | $98.99 |
| Consulting Fee | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $455.79 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $228.34 | 2019-2025 | Dupixent, Libtayo |
| Stryker Corporation | $228.31 | 2019-2022 | |
| Optinose US, INC. | $186.89 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $180.98 | 2022-2023 | |
| Harmony Biosciences LLC | $167.75 | 2022-2025 | Wakix |
| Aerin Medical INC. | $153.09 | 2023-2025 | |
| Genzyme Corporation | $146.18 | 2019-2024 | |
| Acclarent, INC | $136.45 | 2020-2023 | Trudi Nav Cable |
| Novartis Pharmaceuticals Corporation | $120.37 | 2019-2024 | |
| Genentech USA, INC. | $100.49 | 2019-2022 | |
| Kaleo, INC. | $83.25 | 2019-2024 | Auvi-Q |
| Jazz Pharmaceuticals INC. | $72.68 | 2019-2021 | |
| Axsome Therapeutics, INC. | $68.75 | 2024-2025 | Sunosi |
| Phathom Pharmaceuticals, INC. | $60.83 | 2024-2025 | Voquezna |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.62 | 2019-2025 | Tezspire, Fasenra |
| Ars Pharmaceuticals Operations, INC. | $48.23 | 2025 | Neffy |
| Alk-Abello, INC | $47.45 | 2019 | |
| Intersect Ent, INC. | $37.92 | 2020-2022 | |
| Medtronic, INC. | $35.00 | 2024 | Nuvent |
| Integra Lifesciences Corporation | $23.20 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Takeda Pharmaceuticals U.S.A., INC. | $22.32 | 2020 | |
| Pfizer INC. | $20.82 | 2023 | |
| Sanofi US Services INC. | $20.42 | 2024 | |
| Inspire Medical Systems, INC. | $19.80 | 2023 | Inspire |
| Aimmune Therapeutics, INC. | $17.58 | 2021 | |
| Resmed Corp | $17.03 | 2019 | |
| Medtronic USA, INC. | $16.36 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $15.44 | 2024 | |
| Merck Sharp & Dohme LLC | $14.71 | 2019 | |
| Olympus America INC. | $11.41 | 2020 | |
| Cook Medical LLC | $10.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Keszeli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.